Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors

NCT05154630 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
8
Enrollment
INDUSTRY
Sponsor class

Stopped The sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators.

Conditions

Interventions

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.